Abbott Laboratories Ltd maintains its full-year earnings guidance despite one-time costs of an undetermined amount it will incur related to its ongoing recall of Similac and other infant formula brands made at a plant where bacterial contaminations were found.
The US Food and Drug Administration says, upon completing its investigation of facility operated by the firm's Abbott Nutrition division...








